November 9, 2023

Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy

Key Points

Key points are not available for this paper at this time.

Abstract

This review focuses on linking the efficacy and safety of CAR T-cell therapy with tumor burden. Its limitations relative to high tumor burden, systemic inflammation, and immune dysregulation are discussed. Emerging clinical approaches to overcome these obstacles and more effectively incorporate this therapeutic strategy into the treatment paradigm of patients with solid malignant tumors are also described.

Bookmark

Cite This Study

Ventin et al. (Thu,) studied this question.

synapsesocial.com/papers/69d6ca51639f29d8dcab331f https://doi.org/https://doi.org/10.1001/jamaoncol.2023.4504

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia2016 · 1,084 citations
2Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma2018 · 4,044 citations
3Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia2018 · 1,770 citations
4Rapid Deletion and Inactivation of CTLs upon Recognition of a Number of Target Cells over a Critical Threshold2013 · 15 citations
5Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation2021 · 16 citations

Bookmark